9th September 2020 By Selina McKee
The National Institute for Heath and Care
Excellence (NICE) has turned down NHS funding of Celgene's Revlimid
(lenalidomide) as maintenance treatment after an autologous stem cell
transplant for newly diagnosed multiple myeloma in adults.
There is currently no maintenance treatment
for newly diagnosed multiple myeloma in people who have had an autologous stem
cell transplant; the condition is usually monitored until it gets worse.
Clinical trial results show that, compared
with monitoring alone, Revlimid increases how long people live and also extends
the time before the condition gets worse.
However, NICE has concluded in preliminary
guidelines that cost-effectiveness estimates for the drug in this setting “are
uncertain”.
“This is because of limitations in the
cost-effectiveness model, and because the model might not reflect what happens
in the NHS in England,” it said.
Therefore, Revlimid could not be considered
value for money for the NHS when used for this indication, it noted.
No comments:
Post a Comment